Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway

Lancet Oncol. 2003 Jan;4(1):37-44. doi: 10.1016/s1470-2045(03)00959-8.


Tumour resistance and dose-limiting toxic effects restrict treatment with most chemotherapeutic drugs. Elucidation of the mechanisms of these effects could permit the development of ways to improve the effectiveness of currently used agents until better therapeutic agents are developed. Several types of alkylating agents are used in the treatment of cancer. The DNA repair protein, O6-alkylguanine-DNA alkyltransferase (ATase) is an important cellular resistance mechanism to one class of alkylating agents. This enzyme removes potentially lethal damage from DNA and experiments in vitro and in vivo have shown that its inactivation can reverse resistance to such agents. Clinical trials of drugs that inactivate ATase are underway and early results indicate that they are active in tumour tissues. However, the ATase present in normal tissues, particularly bone marrow, is also inactivated, necessitating a reduction in the dose of alkylating agent. An important question is whether, in the absence of any tumour-specific delivery strategy, such drugs will improve therapeutic effectiveness; initial reports are not promising.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Agents, Alkylating / chemistry
  • Antineoplastic Agents, Alkylating / pharmacology*
  • DNA Damage
  • DNA Repair* / drug effects
  • DNA Repair* / physiology
  • Drug Resistance, Neoplasm / physiology
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Nucleotidyltransferases / chemistry
  • Nucleotidyltransferases / drug effects
  • Nucleotidyltransferases / metabolism*
  • O(6)-Methylguanine-DNA Methyltransferase / metabolism


  • Antineoplastic Agents, Alkylating
  • O(6)-Methylguanine-DNA Methyltransferase
  • Nucleotidyltransferases
  • glutamine-synthetase adenylyltransferase